$1.09 Billion is the total value of Casdin Capital, LLC's 32 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 15.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $86,457,000 | -99.9% | 670,000 | -23.9% | 7.95% | +15.9% |
| BLUE | Buy | BLUEBIRD BIO INC | $85,118,000 | -99.8% | 970,000 | +58.4% | 7.83% | +34.5% |
| CDXS | CODEXIS INC | $81,130,000 | -99.9% | 5,073,780 | 0.0% | 7.46% | +3.6% | |
| BPMC | BLUEPRINT MEDICINES CORP | $75,303,000 | -99.9% | 940,000 | 0.0% | 6.92% | -3.1% | |
| MYOK | Sell | MYOKARDIA INC | $73,249,000 | -99.9% | 1,005,000 | -9.9% | 6.74% | +11.9% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $59,313,000 | -99.9% | 515,000 | -14.2% | 5.45% | +9.2% |
| NVTA | Sell | INVITAE CORP | $58,687,000 | -99.9% | 3,638,388 | -5.2% | 5.40% | -29.5% |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $57,132,000 | -99.4% | 1,212,734 | -20.4% | 5.25% | +415.6% |
| BOLD | AUDENTES THERAPEUTICS INC | $51,462,000 | -99.8% | 860,000 | 0.0% | 4.73% | +89.3% | |
| FATE | FATE THERAPEUTICS INC | $49,904,000 | -99.9% | 2,550,000 | 0.0% | 4.59% | +12.0% | |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $46,968,000 | -99.8% | 3,098,121 | +1.6% | 4.32% | +33.5% |
| BLFS | Buy | BIOLIFE SOLUTIONS INC | $39,941,000 | -99.9% | 2,468,571 | +1.6% | 3.67% | -12.1% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $39,394,000 | -99.9% | 825,000 | -11.8% | 3.62% | +15.6% |
| CDNA | Buy | CAREDX INC | $25,884,000 | -99.9% | 1,200,000 | +20.0% | 2.38% | +1.7% |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $23,847,000 | -99.8% | 300,000 | 0.0% | 2.19% | +45.6% | |
| DNLI | Buy | DENALI THERAPEUTICS INC | $21,775,000 | -99.8% | 1,250,000 | +92.3% | 2.00% | +94.2% |
| FULC | Buy | FULCRUM THERAPEUTICS INC | $20,622,000 | -99.6% | 1,239,285 | +46.8% | 1.90% | +226.9% |
| ILMN | ILLUMINA INC | $19,904,000 | -99.9% | 60,000 | 0.0% | 1.83% | -3.1% | |
| GRTS | Buy | GRITSTONE ONCOLOGY INC | $19,375,000 | -99.9% | 2,160,000 | +22.0% | 1.78% | +12.6% |
| ALEC | Buy | ALECTOR INC | $18,540,000 | -99.8% | 1,076,039 | +32.7% | 1.70% | +40.9% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $16,604,000 | -100.0% | 230,000 | -42.5% | 1.53% | -73.7% |
| GNMK | GENMARK DIAGNOSTICS INC | $16,186,000 | -99.9% | 3,365,000 | 0.0% | 1.49% | -29.5% | |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS IN | $15,871,000 | -99.5% | 255,000 | +155.0% | 1.46% | +316.0% |
| VYGR | Sell | VOYAGER THERAPEUTICS INC | $15,276,000 | -99.9% | 1,095,075 | -2.9% | 1.40% | -30.1% |
| ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $13,857,000 | -99.9% | 463,125 | 0.0% | 1.27% | -14.0% | |
| GILD | New | GILEAD SCIENCES INCcall | $12,996,000 | – | 200,000 | +100.0% | 1.20% | – |
| SGMO | SANGAMO THERAPEUTICS INC | $12,178,000 | -99.9% | 1,455,000 | 0.0% | 1.12% | -17.8% | |
| ORTX | Buy | ORCHARD THERAPEUTICS PLCads | $11,275,000 | -99.7% | 820,000 | +164.5% | 1.04% | +172.2% |
| TWST | TWIST BIOSCIENCE CORP | $6,300,000 | -99.9% | 300,000 | 0.0% | 0.58% | -21.9% | |
| TPTX | TURNING POINT THERAPEUTICS I | $4,672,000 | -99.8% | 75,000 | 0.0% | 0.43% | +47.3% | |
| BMYRT | New | BRISTOL MYERS SQUIBB COright 99/99/9999 | $4,515,000 | – | 1,500,000 | +100.0% | 0.42% | – |
| STOK | STOKE THERAPEUTICS INC | $3,682,000 | -99.9% | 130,000 | 0.0% | 0.34% | +17.3% | |
| EDIT | Exit | EDITAS MEDICINE INC | $0 | – | -415,000 | -100.0% | -0.98% | – |
| FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -820,000 | -100.0% | -1.54% | – |
| ONCE | Exit | SPARK THERAPEUTICS INC | $0 | – | -863,300 | -100.0% | -8.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.